Key Determinants Shaping Antimicrobial Resistance Research in Southeast Asia

Effective planning requires understanding the local and regional drivers of antimicrobial resistance research in Southeast Asia. This article maps the main determinants — from governance and surveillance to funding flows, One Health integration, and workforce capacity — and gives a concise framework and checklist to prioritize research investments and program design.

antimicrobial resistance research in Southeast Asia: Determinants and how to prioritize

Overview of determinants

Determinants are the conditions and levers that shape what research is done, how quickly results move into policy, and where evidence gaps persist. The most actionable categories are governance and policy; surveillance and laboratory capacity; financing and incentives; One Health coordination across human, animal and environmental sectors; data systems and standards; and workforce training and retention.

Policy & governance

National AMR action plans, regulatory frameworks for antibiotics, and regional agreements set research priorities and define legal constraints. Where national policies mandate surveillance or reporting, research tends to focus on implementation science and operational improvements. Conversely, weak regulatory systems shift research toward pilot studies and descriptive epidemiology.

Surveillance capacity and data systems

AMR surveillance capacity — including lab quality, standardized testing, and electronic reporting — is a primary determinant of research feasibility. Surveillance gaps constrain longitudinal studies and meta-analysis. Investments in laboratory accreditation and interoperable data platforms increase the return on research funding by enabling multicenter studies and cross-border comparisons.

Financing, incentives, and research funding models

Funding shapes the balance between basic science, applied research, and implementation research. One Health AMR research funding that explicitly supports multi-sector studies tends to produce higher-policy-impact outputs. Short-term project grants often favor single-site studies; larger, flexible grants or pooled regional funds encourage collaborative, translational work.

One Health coordination

AMR emerges across humans, animals, and the environment. Where ministries of health, agriculture, and environment coordinate, research designs can integrate antimicrobial usage data from hospitals, farms, and wastewater, which improves causal inference and policy relevance.

Human behavior, economics, and supply chains

Prescribing practices, over-the-counter availability, informal supply chains, and economic drivers of antimicrobial use are common research targets because they shape both resistance emergence and feasible interventions. Social science and implementation research are essential complements to laboratory studies.

Data standards, sharing, and ethics

Common laboratory standards (for AST methods), metadata schemas, and ethical review pathways determine how easily multi-site and cross-country analyses can be conducted. Harmonizing methods to international standards accelerates evidence synthesis and policy uptake. For global context on standards and burden, see WHO on AMR.

Research capacity and workforce

Human resources — trained microbiologists, epidemiologists, data managers, and implementation scientists — are core determinants. Training programs, career pathways, and retention incentives determine whether research outputs are sustained and translated into policy.

The SCOPE-RE framework (named model)

A practical framework helps prioritize interventions and research questions. The SCOPE-RE framework organizes determinants into six domains to guide assessment and planning:

• Stakeholder alignment (policy, ministries, funders)
• Capacity (labs, human resources, surveillance)
• One Health integration (human, animal, environment)
• Policy & regulatory environment
• Evidence systems (data standards, sharing)
• REsource flows (funding models, incentives)

Use SCOPE-RE as a checklist to map strengths, gaps, and near-term levers for action.

Checklist: Quick assessment

• Is a national AMR action plan in place and funded?
• Are sentinel labs using standardized AST and accredited methods?
• Are cross-sector data linkages (human/animal/environment) feasible?
• Is multi-year funding available for collaborative studies?
• Are data governance and ethics approvals streamlined for multi-site research?

Real-world scenario

Scenario: A provincial hospital in Indonesia documents rising carbapenem resistance but lacks routine environmental sampling and animal-sector data. Applying SCOPE-RE shows gaps in One Health coordination and data standards. A combined intervention that secures short-term funding for lab upgrades, establishes animal-health sampling, and aligns reporting templates results in a regional study that informs antibiotic stewardship and agricultural use policies.

Practical tips (actionable)

1. Map stakeholders early: identify ministry leads across sectors and convene a short technical working group to agree on priority questions.
2. Invest in a minimal data standard: adopt one AST method and metadata schema for all sites to enable aggregation.
3. Design funding portfolios with mixed timelines: include short-term pilots plus multi-year collaborative grants to ensure scale-up pathways.
4. Build short, targeted training modules for lab staff and data managers to accelerate accreditation.
5. Use pilot studies to demonstrate policy relevance: tie at least one output to a clear decision (e.g., antibiotic formulary change).

Trade-offs and common mistakes

Trade-offs are inevitable. Investing heavily in advanced genomics without strengthening basic AST and surveillance may produce impressive papers but limited policy impact. Common mistakes include under-resourcing data management, ignoring animal/environment data, and funding only short-term projects that cannot scale. Balance technical ambition with system-level investments.

FAQ

What is the current landscape of antimicrobial resistance research in Southeast Asia?

Research is heterogeneous: some countries have robust surveillance networks and laboratory capacity; others are building basic systems. Active areas include surveillance, stewardship interventions, and social science on antibiotic use. Cross-border and One Health studies are growing but limited by data standardization and funding duration.

How can AMR surveillance capacity be measured and improved?

Measure capacity by lab accreditation status, percentage of sentinel sites reporting timely data, and completeness of metadata. Improvements follow a phased approach: (1) standardize AST methods, (2) strengthen QA/QC, (3) train staff, and (4) implement electronic reporting.

Which funding models support One Health AMR research best?

Pooled regional funds or multi-year grants that require cross-sector partners produce more integrated outputs than single-institution short grants. Incentivize data sharing and dedicate a portion of funds to capacity building and maintenance.

How should policymakers balance short-term needs and long-term AMR research goals?

Allocate a portion of budgets to rapid-response operational research tied to immediate program needs and reserve multi-year funding for systems strengthening, surveillance expansion, and translational studies that can inform national policy.

What are initial steps for a country to strengthen AMR research coordination?

Establish a multi-sector technical working group, adopt a shared data standard, map existing funding and capacity, and pilot a joint surveillance project linking a human hospital, a veterinary site, and an environmental sampling point.